1 / 1

In pediatric patients with ≥ 2 prior inductions 9 of 39 (23%) of patients had

Question for the Committee. In pediatric patients with ≥ 2 prior inductions 9 of 39 (23%) of patients had CR or CR*. Four of 9 CR or CR* patients who did not have their CR or CR* duration confounded by subsequent Transplant or other Systemic

morrie
Télécharger la présentation

In pediatric patients with ≥ 2 prior inductions 9 of 39 (23%) of patients had

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Question for the Committee • In pediatric patients with ≥ 2 prior inductions 9 of 39 (23%) of patients had • CR or CR*. Four of 9 CR or CR* patients who did not have their CR or • CR* duration confounded by subsequent Transplant or other Systemic • chemotherapy had CR or CR* durations of 3.3, 3.6, 6.1 and 9.3 weeks • Are these results reasonably likely to predict clinical benefit in this setting? • In adult patients with ≥ 2 prior inductions 6 of 28 (21%) of patients had CR • or CR*. Five of 6 CR or CR* patients who did not have their CR or CR* • duration confounded by subsequent Transplant or other Systemic • chemotherapy had CR or CR* durations of 4, 15, 19, 30 and 195 +weeks. • Are these results reasonably likely to predict clinical benefit in this setting? • Is the benefit/risk ratio favorable? • Should this NDA be granted accelerated approval?

More Related